Upgrade to SI Premium - Free Trial

Needham Reiterates Buy Rating on Neogenomics (NEO)

July 30, 2024 6:04 AM
Needham analyst Mike Matson reiterated a Buy rating and $19.00 price target on Neogenomics (NASDAQ: NEO).The analyst comments "NEO's 2Q24 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles